123 related articles for article (PubMed ID: 7874569)
1. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Turrill M; Spicer DV; Kelley AS; Herman RL; Russell CA; Muggia FM
Cancer Invest; 1995; 13(2):160-4. PubMed ID: 7874569
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
[TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Sanchiz F; Milla A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
Williamson SK; Wolf MK; Eisenberger MA; O'Rourke MA; Brannon W; Crawford ED
Am J Clin Oncol; 1996 Aug; 19(4):368-70. PubMed ID: 8677906
[TBL] [Abstract][Full Text] [Related]
5. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer.
Hsieh RK; Chang AY; Boros L; Asbury R
Am J Clin Oncol; 1994 Dec; 17(6):509-13. PubMed ID: 7977171
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
9. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Goren MP; McKenna LM; Goodman TL
Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
Le Chevalier T; Thomas F; Subirana R; Baldeyrou P; Ruffie P; Arriagada R; Chazard M; Tursz T
Cancer; 1991 Jun; 67(12):2980-3. PubMed ID: 1646067
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
[TBL] [Abstract][Full Text] [Related]
13. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience.
Postmus PE; Smit EF; Berendsen HH; Haaxma-Reiche H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):17-23. PubMed ID: 1329219
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of mesna with ifosfamide.
Goren MP
Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer.
Kiraz S; Baltali E; Güler N; Barista I; Benekli M; Celik I; Güllü IH; Kars A; Tekuzman G; Firat D
J Chemother; 1996 Aug; 8(4):310-4. PubMed ID: 8873839
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Walters RS; Holmes FA; Valero V; Esparza-Guerra L; Hortobagyi GN
Am J Clin Oncol; 1998 Aug; 21(4):413-5. PubMed ID: 9708645
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-108-S2-112. PubMed ID: 9045327
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial.
Campisi C; Fabi A; Papaldo P; Tomao S; Massidda B; Zappala A; Ionta MT; Cognetti F
Cancer Chemother Pharmacol; 1999; 44 Suppl():S1-4. PubMed ID: 10602901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
